Health care stocks were declining premarket Friday as the Health Care Select Sector SPDR Fund (XLV) was down 0.4% and the iShares Biotechnology ETF (IBB) was 0.2% lower recently.
Novo Nordisk (NVO) shares rose past 11% after the company said its phase 1b/2a clinical trial of amycretin in people with overweight or obesity showed positive results.
Allurion Technologies (ALUR) shares surged by more than 364% after the company said it plans to initiate a clinical study to investigate the combination of the Allurion program with GLP-1 agonists to improve muscle mass and overall body composition.
Moderna (MRNA) shares were up over 1% after the company said it has been awarded a tender to supply its Covid-19 vaccine in the European Union, Norway and North Macedonia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.